Office of Women’s Health Gets Short-changed

J0409703Are the women of America suddenly facing less health concerns than they have been for the sixteen years?  Common sense probably says the answer is no.  But common sense does not appear to be involved in FDA budgeting decisions.

For the past 16 years, Congress has allocated $4 million towards the Office of Womens Health (OWH).  However, this week it became apparent that $1.2 million dollar’s worth of that budget was disappearing, despite congressional and presidential requests to the contrary.  What gives?

The move prompted the Society for Women’s Health Research to state their opposition to these cuts and also brought protest from the three former directors of the OWH, both statements being exhibited at OBGYN.net

According to the Washington Post article on the issue from February 27, this cut will effectively shut down the OWH activities for the balance of the year.  Reportedly, the OWH will, as a result of the cuts, have committed this year to spending more money than it actually has left in its budget.  Who operates an agency that way?

As you may recall, the OWH was at the center of the Plan B controversy and its director resigned because of the FDA’s fumbled handling of Plan B.  Is the budget cut someone’s way of issuing payback to the OWH?  Such concerns were expressed by several who were interviewed for the article.  In the absence of any other explanation, such a point of view will no doubt stick.

But this is hardly the kind of perception this beleaguered and highly troubled agency needs at this time.  Every single act by the agency should be a step to restoring its reputation, not subjecting it to further question and scrutiny.  About the smartest thing that the FDA has accomplished in the past year is to put the Plan B fiasco behind it.  If the concerns regarding retribution true, the action is not only ham-handed, it fuels the flames of doubt over the agency has become more political than scientific under this Administration and undermines any ability of the FDA to move on from the morass in which it is stuck. 

Several Senators also joined the chorus and called on the Commissioner to see to it that this cut is reversed.  If he knows what he is doing, Dr. von Eshenbach will make sure that the cut is not only immediately restored, but that this sort of action not occur in the future. 

Share this:
Share this page via Email Share this page via Stumble Upon Share this page via Digg this Share this page via Facebook Share this page via Twitter
This entry was posted in Current Affairs, FDA Image. Bookmark the permalink.

One Response to Office of Women’s Health Gets Short-changed

  1. pfd2007 says:

    If you listen carefully to Eschenbach’s comments when testifying before Congress on the issue, he says the FDA will not lessen its commitment to women’s health. What is absent from his comments is support for the Office of Women’s Health.
    Some FDA leaders think the agency’s centers can handle women’s health on their own without direction from a central, coordinating office located under the administrator. The centers don’t have a strong history in this area. That’s why OWH was created in the first place, and it is the chief reason to be concerned about it losing funding.